Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis

Daniela A Moraes,1 Maria Carolina Oliveira2 1Division of Clinical Immunology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil; 2Center for Cell-Based Therapy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Moraes DA, Oliveira MC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	systemic sclerosis stem cell transplantation long-term outcomes progression-free survival Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/b81e961720494f009ba5679a8878dfd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b81e961720494f009ba5679a8878dfd4
record_format	dspace
spelling	oai:doaj.org-article:b81e961720494f009ba5679a8878dfd42021-11-09T18:40:35ZLife after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis1179-2736https://doaj.org/article/b81e961720494f009ba5679a8878dfd42021-11-01T00:00:00Zhttps://www.dovepress.com/life-after-autologous-hematopoietic-stem-cell-transplantation-for-syst-peer-reviewed-fulltext-article-JBMhttps://doaj.org/toc/1179-2736Daniela A Moraes,1 Maria Carolina Oliveira2 1Division of Clinical Immunology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil; 2Center for Cell-Based Therapy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, BrazilCorrespondence: Maria Carolina OliveiraDepartment of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP, 14048-900, BrazilEmail mcarolor@usp.brAbstract: Stem cell transplantation has been investigated as treatment for severe and progressive systemic sclerosis (SSc) for the past 25 years. To date, more than 1000 SSc patients have been transplanted worldwide. Overall and event-free survival have increased over the years, reflecting stricter patient selection criteria and better clinical management strategies. This review addresses long-term outcomes of transplanted SSc patients, considering phase I/II and randomized clinical trials, as well as observational studies and those assessing specific aspects of the disease. Clinical outcomes are discussed comparatively between studies, highlighting advances, drawbacks and controversies in the field. Areas for future development are also discussed.Keywords: systemic sclerosis, stem cell transplantation, long-term outcomes, progression-free survivalMoraes DAOliveira MCDove Medical Pressarticlesystemic sclerosisstem cell transplantationlong-term outcomesprogression-free survivalDiseases of the blood and blood-forming organsRC633-647.5ENJournal of Blood Medicine, Vol Volume 12, Pp 951-964 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	systemic sclerosis stem cell transplantation long-term outcomes progression-free survival Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	systemic sclerosis stem cell transplantation long-term outcomes progression-free survival Diseases of the blood and blood-forming organs RC633-647.5 Moraes DA Oliveira MC Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
description	Daniela A Moraes,1 Maria Carolina Oliveira2 1Division of Clinical Immunology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil; 2Center for Cell-Based Therapy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, BrazilCorrespondence: Maria Carolina OliveiraDepartment of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Avenida dos Bandeirantes, 3900, Ribeirão Preto, SP, 14048-900, BrazilEmail mcarolor@usp.brAbstract: Stem cell transplantation has been investigated as treatment for severe and progressive systemic sclerosis (SSc) for the past 25 years. To date, more than 1000 SSc patients have been transplanted worldwide. Overall and event-free survival have increased over the years, reflecting stricter patient selection criteria and better clinical management strategies. This review addresses long-term outcomes of transplanted SSc patients, considering phase I/II and randomized clinical trials, as well as observational studies and those assessing specific aspects of the disease. Clinical outcomes are discussed comparatively between studies, highlighting advances, drawbacks and controversies in the field. Areas for future development are also discussed.Keywords: systemic sclerosis, stem cell transplantation, long-term outcomes, progression-free survival
format	article
author	Moraes DA Oliveira MC
author_facet	Moraes DA Oliveira MC
author_sort	Moraes DA
title	Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
title_short	Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
title_full	Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
title_fullStr	Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
title_full_unstemmed	Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
title_sort	life after autologous hematopoietic stem cell transplantation for systemic sclerosis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/b81e961720494f009ba5679a8878dfd4
work_keys_str_mv	AT moraesda lifeafterautologoushematopoieticstemcelltransplantationforsystemicsclerosis AT oliveiramc lifeafterautologoushematopoieticstemcelltransplantationforsystemicsclerosis
_version_	1718440875950866432

Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis

Ejemplares similares